Estimating the association between being seropositive for cysticercosis and the prevalence of epilepsy and severe chronic headaches in 60 villages of rural Burkina Faso.
Adolescent
Adult
Aged
Aged, 80 and over
Animals
Antigens, Helminth
/ blood
Burkina Faso
/ epidemiology
Child
Cross-Sectional Studies
Epilepsy
/ epidemiology
Female
Headache Disorders
/ epidemiology
Humans
Male
Middle Aged
Neurocysticercosis
/ complications
Prevalence
Randomized Controlled Trials as Topic
Rural Population
Surveys and Questionnaires
Taenia solium
/ isolation & purification
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
30
03
2018
accepted:
19
12
2018
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
12
2
2019
Statut:
epublish
Résumé
Individuals diagnosed with neurocysticercosis often present with epilepsy and sometimes with progressively worsening severe chronic headaches (WSCH). While cross-sectional associations between seropositivity to cysticercal antigens and epilepsy have been reported, few large scale studies have been conducted in West Africa and none have measured the association between seropositivity to cysticercal antigens and headaches. This study aimed at filling these knowledge gaps by estimating the strength of the cross-sectional association between seropositivity to cysticercal antigens and the prevalence of epilepsy and WSCH in 60 villages of Burkina Faso, West Africa. Baseline data from a cluster randomized controlled trial collected from January 2011 to February 2012 in 60 villages across three provinces in Burkina Faso were used. Between 78 and 80 individuals were screened for epilepsy and WSCH in each village, and those screened positive were confirmed by a physician. Seventy-five percent of all participants were asked to provide a blood sample to test for Taenia solium cysticercus circulating antigens. Hierarchical multivariable logistic models were used to measure the association between seropositivity to cysticercal antigens and epilepsy (lifetime and active) as well as WSCH. Among 3696 individuals who provided a blood sample, 145 were found to have epilepsy only, 140 WSCH only and 19 both. There were positive associations between seropositivity to cysticercal antigens and active epilepsy (prevalence odds ratio (POR): 2.40 (95%CI: 1.15-5.00)) and WSCH (POR: 2.59 (1.34-4.99)). Our study is the first to demonstrate a cross-sectional association between seropositivity to cysticercal antigens and WSCH in a large community-based study conducted in West Africa. The measured cross-sectional association had a strength similar to the ones previously observed between seropositivity to cysticercal antigens and lifetime or active epilepsy. As a result, preventing new cysticercosis cases in communities may reduce the prevalence of these two important neurological disorders.
Sections du résumé
BACKGROUND
Individuals diagnosed with neurocysticercosis often present with epilepsy and sometimes with progressively worsening severe chronic headaches (WSCH). While cross-sectional associations between seropositivity to cysticercal antigens and epilepsy have been reported, few large scale studies have been conducted in West Africa and none have measured the association between seropositivity to cysticercal antigens and headaches. This study aimed at filling these knowledge gaps by estimating the strength of the cross-sectional association between seropositivity to cysticercal antigens and the prevalence of epilepsy and WSCH in 60 villages of Burkina Faso, West Africa.
METHODOLOGY/PRINCIPAL FINDINGS
Baseline data from a cluster randomized controlled trial collected from January 2011 to February 2012 in 60 villages across three provinces in Burkina Faso were used. Between 78 and 80 individuals were screened for epilepsy and WSCH in each village, and those screened positive were confirmed by a physician. Seventy-five percent of all participants were asked to provide a blood sample to test for Taenia solium cysticercus circulating antigens. Hierarchical multivariable logistic models were used to measure the association between seropositivity to cysticercal antigens and epilepsy (lifetime and active) as well as WSCH. Among 3696 individuals who provided a blood sample, 145 were found to have epilepsy only, 140 WSCH only and 19 both. There were positive associations between seropositivity to cysticercal antigens and active epilepsy (prevalence odds ratio (POR): 2.40 (95%CI: 1.15-5.00)) and WSCH (POR: 2.59 (1.34-4.99)).
CONCLUSIONS/SIGNIFICANCE
Our study is the first to demonstrate a cross-sectional association between seropositivity to cysticercal antigens and WSCH in a large community-based study conducted in West Africa. The measured cross-sectional association had a strength similar to the ones previously observed between seropositivity to cysticercal antigens and lifetime or active epilepsy. As a result, preventing new cysticercosis cases in communities may reduce the prevalence of these two important neurological disorders.
Identifiants
pubmed: 30677038
doi: 10.1371/journal.pntd.0007101
pii: PNTD-D-18-00506
pmc: PMC6345432
doi:
Substances chimiques
Antigens, Helminth
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007101Subventions
Organisme : NINDS NIH HHS
ID : F31 NS093983
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS064901
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD007338
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cephalalgia. 2010 Jan;30(1):62-7
pubmed: 19489885
PLoS Negl Trop Dis. 2015 Nov 20;9(11):e0004248
pubmed: 26588468
Epilepsia. 2010 May;51(5):883-90
pubmed: 20067507
Cephalalgia. 2007 Mar;27(3):193-210
pubmed: 17381554
Lancet Neurol. 2005 Jan;4(1):21-31
pubmed: 15620854
Epilepsia. 2003 Jul;44(7):950-5
pubmed: 12823579
Acta Neurol Scand. 2012 Oct;126(4):270-8
pubmed: 22289127
Sci Rep. 2014 Aug 15;4:6085
pubmed: 25124526
Lancet Neurol. 2014 Dec;13(12):1202-15
pubmed: 25453460
Cephalalgia. 2004 Nov;24(11):960-6
pubmed: 15482359
PLoS Negl Trop Dis. 2017 Mar 7;11(3):e0005153
pubmed: 28267746
Lancet Glob Health. 2018 Apr;6(4):e411-e425
pubmed: 29530423
Epilepsia. 2010 May;51(5):830-7
pubmed: 19919664
Ann Trop Med Parasitol. 1995 Dec;89(6):689-92
pubmed: 8745945
PLoS Negl Trop Dis. 2012;6(10):e1851
pubmed: 23094118
Cephalalgia. 2008 Nov;28(11):1107-14
pubmed: 18727634
Epilepsy Res. 2012 May;99(3):318-26
pubmed: 22281063
Epilepsia. 2012 Dec;53(12):2194-202
pubmed: 23148555
Epilepsy Curr. 2004 May-Jun;4(3):107-11
pubmed: 16059465
Lancet Neurol. 2008 Dec;7(12):1099-105
pubmed: 18986841
Epidemiology. 2011 Sep;22(5):745
pubmed: 21811114
Bull Soc Pathol Exot. 2004 May;97(2):105-8
pubmed: 15255351
Lancet Neurol. 2008 Apr;7(4):354-61
pubmed: 18339350
Headache. 1995 Feb;35(2):93-7
pubmed: 7737869
PLoS Negl Trop Dis. 2011 May;5(5):e1152
pubmed: 21629722
PLoS Negl Trop Dis. 2009 Nov 24;3(11):e555
pubmed: 19936298
PLoS Negl Trop Dis. 2010 Sep 07;4(9):
pubmed: 20838646
Lancet Neurol. 2013 Mar;12(3):253-63
pubmed: 23375964
Am J Trop Med Hyg. 2018 Sep;99(3):729-734
pubmed: 29943721
Epilepsia. 2005 Apr;46(4):470-2
pubmed: 15816939
Bull Soc Pathol Exot. 2000 Nov;93(4):276-8
pubmed: 11204728
East Afr Med J. 1992 Apr;69(4):196-9
pubmed: 1644029
Neuroimaging Clin N Am. 2012 Nov;22(4):659-76
pubmed: 23122261
Cephalalgia. 2009 Dec;29(12):1317-25
pubmed: 19438921
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29875195
Lancet. 2003 Aug 16;362(9383):547-56
pubmed: 12932389
Neuroepidemiology. 2014;42(1):7-15
pubmed: 24356059
Am J Trop Med Hyg. 2018 Feb;98(2):565-569
pubmed: 29280427
Cephalalgia. 2010 May;30(5):582-92
pubmed: 19735479
Epilepsia. 2014 Apr;55(4):475-82
pubmed: 24730690
Infect Dis Poverty. 2017 Jun 1;6(1):95
pubmed: 28569208
Lancet Neurol. 2005 Oct;4(10):653-61
pubmed: 16168934
Int J Parasitol. 2004 Apr;34(5):569-76
pubmed: 15064121
Cephalalgia. 1995 Dec;15(6):482-8
pubmed: 8706111